Clinical trial

A Placebo-Controlled, Double-Blinded, Randomized Trial of Remicade in Korean…

NCT00202852 · Merck Sharp & Dohme LLC, Industry · Completed

Key facts

NCT number NCT00202852
Title A Placebo-Controlled, Double-Blinded, Randomized Trial of Remicade in Korean Patients With Rheumatoid Arthritis Despite Methotrexate (Study P04280)(COMPLETED)
Official title A Placebo-Controlled, Double-Blinded, Randomized Clinical Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Korean Patients With Active Rheumatoid Arthritis Despite Methotrexate
Lead sponsor Merck Sharp & Dohme LLC, Industry
Status Completed
Phase Phase 3
Study type Interventional
Conditions Arthritis, Rheumatoid
Intervention type Biological, Drug, Other
Interventions Placebo, MTX, Infliximab
Enrollment 143
Start date Jun 1, 2005
Primary completion Mar 1, 2006
Completion Mar 1, 2006
First posted Sep 20, 2005
Last update posted Mar 24, 2017

At a glance

  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies